Abstract
The prognosis for patients with respiratory syncytial virus (RSV) or parainfluenza virus type 3 (PIV3) respiratory tract infection post allogeneic haematopoietic progenitor cell transplant (HPCT) is historically poor. The use of oral ribavirin (RBV) has not been widely studied in this patient population. We examined the outcomes of 15 consecutive patients (RSV, n=13 and PIV3, n=2) treated with oral RBV post HPCT. Oral RBV was commenced at a starting dose of 10 mg/kg/day, increasing to a maximum dose of 60 mg/kg/day depending on response and tolerance. At diagnosis, seven patients had upper respiratory tract infection (URTI) and eight had lower respiratory tract infection (LRTI). The starting RBV dose of 10 mg/kg/day did not prevent the progression of URTI to LRTI in any patient. However, with dose escalation, six of the seven patients responded to RBV therapy and survived their infective episode. Of the eight patients presenting with LRTI, six patients survived their infection, again after dose escalation of RBV. There was no dose-limiting toxicity seen in any patient. Our results indicate that oral RBV has clinical efficacy in the treatment of RSV/PIV3 infection post HPCT. However, a starting dose of 10 mg/kg/day appears ineffective; we recommend a starting dose of 20 mg/kg/day in this patient group.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA et al. An outbreak of respiratory synsitial virus in a Bone Marrow transplant center. J Infect Dis 1992; 165: 987–993.
Lewis VA, Champlin R, Englund J, Couch R, Goodrich JM, Rolston K et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipeints. Clin Infect Dis 1996; 23: 1033–1037.
Nichols WG, Gooley T, Boeckh M . Community-acquired respiratory synsitial virus and parainfluenza virus infections after hematopoetic stem cell transplantation: The Fred Hutchinson Cancer Research Center experience. Biol Blood Bone Marrow Trans 2001; 7: 11s–15s.
Wendt CW, Weisdorf DJ, Jordan C, Balfour HH, Hertz MI . Parainfluenza virus respiratory infection after bone marrow transplantation. NEJM 1992; 326: 921–926.
Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P . Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Chemother 1999; 43: 2451–2456.
Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory synsitial virus upper respiratory tract infection in hematopoetic cell transplant recipients. Clin Infect Dis 2007; 44: 245–249.
Bowden RA . Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center Experience. Am J Med 1997; 102: 27–30.
Sparrelid E, Ljunman P, Ekelof-Andstrom E, Aschan J, Ringden O, Winiarski J et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997; 19: 905–908.
Shah JN, Chemaly RF . Management of RSV infections in adult recipeints of hemopoetic stem cell transplant. Blood 2011; 117: 2755–2763.
Lambert SB, Whiley DM, O’Neill NT, Andrews EC, Canavan FM, Bletchly C et al. Comparing nose-throat swabs and nasopharyngeal aspirates from children with symptoms for respiratory virus identification using real-time polymerase chain reaction. Pediatrics 2008; 122: e615–e620.
Hisrsh HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P . Fourth European conference on infections in leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus and coronavirus. Clin Infect Dis 2013; 56: 256–266.
Avetisyan G, Mattsson J, Sparrelid E, Ljungman P . Respitarory syncytial virus infection in receipients of allogenic stem cell transplantation: a retropsective study of the incidence, clinical features and outcome. Transplantation 2009; 88: 1222–1226.
Chemaly RF, Hanmod SS, Rathod DB, Ghantoji SS, Jiang Y, Doshi A et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukaemia or recipients of hematopoietic stem cell transplantation. Blood 2012; 19: 2738–2748.
Elizaga J, Olivarria E, Apperley JF, Goldman JM, Ward KN . Parainfluenza virus 3 infection after stem cell transplant: relevance of outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001; 32: 413–418.
Hassan IA, Chopra R, Swindell R, Mutton KJ . Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant 2003; 32: 73–77.
Hodson A, Kasliwal M, Streetly M, MacMahon E, Raj K . A parainfluenza-3 outbreak in SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality. Bone Marrow Transplant 2011; 46: 1545–1550.
Khanna N, Widmer A, Decker M, Steffen I, Halter J, Heim D et al. Respiratory synsitial virus infection in patients with hematological disease: single-centre study and review of the literature. Clin Infect Dis 2008; 46: 402–412.
Ljungman P, Ward KN, Crooks BNA, Parker A, Martino R, Shaw PJ et al. Respiratory virus infections after stem cell transplantation: a prospective study from the infectious diseases working party of the European group for blood and marrow transplantation. Bone Marrow Transplant 2001; 28: 479–484.
Machado CM, Boas LSV, Mendes AVA, Santos MFM, da Rocha IF, Sturaro D et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant 2003; 31: 695–700.
Maziarz RT, Sridharan P, Slater S, Meyers G, Post M, Erdman D et al. Control of an outbreak of human parainfluenza virus 3 in hematopoetic stem cell transplant recipients. Biol Blood Marrow Transplant 2010; 16: 192–198.
Nichols WG, Corey L, Gooley T, Davis C, Boeckh M . Parainfluenza virus infections after hematopoetic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98: 573–578.
Chakrabarti S, Collingham KE, Holder K, Oyaide S, Pillay D, Milligan DW . Parainfluenza 3 virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy. Clin Infect Dis 2000; 31: 1516–1518.
Ariza-Heredia EJ, Fishman JE, Cleary T, Smith L, Razonable RR, Abbo L et al. Clinical and radiological features of respiratory syncytical virus in solid organ transplant recipients: a single-center experience. Transplant Infect Dis 2012; 14: 64–71.
Glanville AR, Scott AI, Morton JM, Aboyoun CL, Plitt ML, Carter IW et al. Intravenous ribavirin is a safe and cost effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005; 24: 2114–2119.
Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L . Oral virus inhaled ribavirin therapy for respiratory syncytical virus infection after lung transplantation. J Heart Lung Transplant 2012; 31: 839–844.
Pelaez A, Lyon GM, Force SD, Ramiez AM, Neujahr DC, Foster M . Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 2009; 28: 67–71.
Chakrabarti S, Collingham KE, Holder K, Fegan CD, Osman H, Milligan DW . Pre-emptive oral ribivirin therapy for paramyxomavirus infections after haematopoietic stem cell transplant: a pilot study. Bone Marrow Transplant 2001; 28: 759–763.
Buckingham SC, Jafri HS, Bush AJ, Carubelli C, Sheerman P, Hardy RD et al. A randomised, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis 2002; 185: 1222–1228.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Disclaimer
No financial assistance or support was received by any author for the conduct of this research.
Rights and permissions
About this article
Cite this article
Casey, J., Morris, K., Narayana, M. et al. Oral ribavirin for treatment of respiratory syncitial virus and parainfluenza 3 virus infections post allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 48, 1558–1561 (2013). https://doi.org/10.1038/bmt.2013.112
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2013.112
Keywords
This article is cited by
-
Impact of multiplexed respiratory viral panels on infection control measures and antimicrobial stewardship: a review of the literature
European Journal of Clinical Microbiology & Infectious Diseases (2022)
-
Evaluation of prognostic scores for respiratory syncytial virus infection in a French multicentre cohort of allogeneic haematopoietic stem cell transplantation recipients
Bone Marrow Transplantation (2021)
-
Immunodeficiency risk score for prediction of mortality by parainfluenza virus infection in patients with hematologic malignancy
Annals of Hematology (2020)
-
Are We Overlooking the Use of Oral Ribavirin for Respiratory Syncytial Virus Infection Following Hematopoietic Stem Cell Transplantation?
Current Treatment Options in Infectious Diseases (2019)
-
The IMPDH inhibitors, ribavirin and mycophenolic acid, inhibit peste des petits ruminants virus infection
Veterinary Research Communications (2018)